Rare molecular subtypes of lung cancer
Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
Targeted therapy for lung cancer: Beyond EGFR and ALK
M Herrera‐Juárez, C Serrano‐Gómez… - Cancer, 2023 - Wiley Online Library
Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
[HTML][HTML] Clinical application of the AMOY 9-in-1 panel to lung cancer patients
K Kunimasa, S Matsumoto, T Kawamura, T Inoue… - Lung Cancer, 2023 - Elsevier
Introduction To investigate the clinical performance of the AMOY 9-in-1 kit (AMOY) in
comparison with a next-generation sequencing (NGS) panel in lung cancer patients …
comparison with a next-generation sequencing (NGS) panel in lung cancer patients …
Precision oncology: 2022 in review
E Rosen, A Drilon, D Chakravarty - Cancer discovery, 2022 - AACR
Precision Oncology: 2022 in Review | Cancer Discovery | American Association for Cancer
Research Skip to Main Content Advertisement Umbrella Alt Text Umbrella Alt Text Close …
Research Skip to Main Content Advertisement Umbrella Alt Text Umbrella Alt Text Close …
[HTML][HTML] Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
MSC Li, KKS Mok, TSK Mok - Annals of Translational Medicine, 2023 - ncbi.nlm.nih.gov
Methods We searched all original papers and reviews on targeted therapy and
immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search …
immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search …
[HTML][HTML] Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Q Chen, G Jia, X Zhang, W Ma - Frontiers in Immunology, 2024 - frontiersin.org
Receptor tyrosine kinases (RTKs) play a crucial role in cellular signaling and oncogenic
progression. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have …
progression. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have …
[HTML][HTML] Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
E Brozos-Vázquez, M Toledano-Fonseca… - Cancer Treatment …, 2024 - Elsevier
Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers,
few advances have been made in recent years. The only curative option is surgery, but only …
few advances have been made in recent years. The only curative option is surgery, but only …
[HTML][HTML] Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
JJ Adashek, C Pandya, NJ Maragakis, P De, PR Cohen… - BMC medicine, 2024 - Springer
Abstract Background Neuregulin-1 (NRG1) is implicated in both cancer and neurologic
diseases such as amyotrophic lateral sclerosis (ALS); however, to date, there has been little …
diseases such as amyotrophic lateral sclerosis (ALS); however, to date, there has been little …
Next-generation therapies for pancreatic cancer
CW Buckley, EM O'Reilly - Expert Review of Gastroenterology & …, 2024 - Taylor & Francis
Introduction Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that
poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC …
poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC …
The evolving landscape of tissue‐agnostic therapies in precision oncology
Tumor‐agnostic therapies represent a paradigm shift in oncology by altering the traditional
means of characterizing tumors based on their origin or location. Instead, they zero in on …
means of characterizing tumors based on their origin or location. Instead, they zero in on …